Strata-X-Drug B

Significance of the Topic

Efficient and reliable extraction of basic drugs of abuse from biological matrices is critical for clinical, forensic, and QA/QC laboratories. Strata-X-Drug B polymeric SPE sorbent addresses common challenges in solid-phase extraction by combining strong cation-exchange chemistry with a simplified workflow that reduces solvent consumption, processing time, and method variability.

Objectives and Overview

This application note introduces two SPE products: Strata-X-Drug B for standard SPE of basic drugs in urine and plasma, and Strata-X-Drug B Plus for in-well β-glucuronidase hydrolysis in 96-well format. The goal is to demonstrate high recoveries, low batch-to-batch variation, and simplified protocols for extracting over 22 SAMHSA-regulated analytes with minimal conditioning steps.

Methodology and Instrumentation

The core methodology employs a polymeric strong cation-exchange sorbent that requires no pre-conditioning, allowing direct loading of acidified samples. After sample loading, impurities are washed off with aqueous and organic solvents, and analytes are eluted with a basic organic mixture. Strata-X-Drug B Plus integrates in-well enzymatic hydrolysis using β-glucuronidase in a 96-well SPE plate aided by Solvent Shielding Technology™ to retain aqueous solutions for up to six hours.

• Sample pre-treatment: Acidification and, for Drug B Plus, in-well incubation with β-glucuronidase for 30 min–3 h.
• Loading: Direct vacuum-assisted application at pH 4–6.
• Washing: Sequential aqueous buffer and organic washes to remove matrix interferences.
• Elution: Dual organic/basic solvent elution to recover analytes.
• Instrumental analysis: LC-MS/MS using Kinetex and Luna Omega columns; optional GC analysis with Zebron columns.

Main Results and Discussion

Strata-X-Drug B achieved recoveries > 96 % for 22 basic drugs of abuse in urine, with intra-batch CVs ≤ 3 % and linearity (r² > 0.995) across relevant SAMHSA cutoff levels. For plasma extraction of methylphenidate, recoveries ranged from 82 % to 99 % at low to high QC levels, with CVs of 6–7 %. Batch-to-batch consistency and uniform flow rates ensured reproducible performance.

Benefits and Practical Applications

• Time savings: Elimination of conditioning steps and in-well hydrolysis removes transfer steps, reducing hands-on time.
• Solvent and cost reduction: Consolidated methods and minimized consumables lower operational expenses.
• Method consolidation: A single sorbent accommodates multiple drug classes, simplifying method development.
• High throughput: Compatibility with 96-well plates and positive-pressure manifolds supports large-scale testing.

Future Trends and Potential Uses

Ongoing trends include integration of high-throughput SPE platforms and automation for forensic and clinical toxicology. Expanded polymeric sorbents may target neutral and acidic metabolites. Coupling with advanced LC-MS and high-resolution MS systems will further enhance sensitivity and selectivity in complex matrices.

Conclusion

Strata-X-Drug B and Drug B Plus offer a robust, versatile, and streamlined SPE solution for basic drugs of abuse in urine and plasma, delivering high recoveries, exceptional reproducibility, and practical workflow advantages for modern analytical laboratories.

Reference

None provided in the source document.